ICARES MedicusROCO:6612 -1.52%84 ROE % is 4.14% as of Dec. 2025, which is 54% below its 10-year median of 9.04. GuruFocus rates ROCO:6612 with a GF Score™ of 84/100 and a GF Value™ of NT$189.06 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 797 Medical Devices & Instruments companies, ICARES Medicus ranks better than 52.32% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. ICARES Medicus's annualized net income for the quarter that ended in Dec. 2025 was NT$74 Mil. ICARES Medicus's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was NT$1,793 Mil. Therefore, ICARES Medicus's annualized ROE % for the quarter that ended in Dec. 2025 was 4.14%.
The historical rank and industry rank for ICARES Medicus's ROE % or its related term are showing as below:
ROCO:6612'
s ROE % Range Over the Past 10 Years
Min: 2.93 Med: 9.04 Max: 15.86
Current: 2.99
During the past 13 years, ICARES Medicus's highest ROE % was 15.86%. The lowest was 2.93%. And the median was 9.04%.
ROCO:6612's ROE % is ranked better than 52.32% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs ROCO:6612: 2.99
ICARES Medicus (ROCO:6612) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
ICARES Medicus ROE % Related Terms
ICARES Medicus ROE % Historical Data
* Premium members only.
The historical data trend for ICARES Medicus's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, ICARES Medicus's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICARES Medicus ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICARES Medicus's ROE % distribution charts can be found below:
* The bar in red indicates where ICARES Medicus's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
ICARES Medicus (ROCO:6612) has a ROE % of 4.14% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ICARES Medicus and its competitors. This is 54% below median its historical median of 9.04. Over the past decade, ICARES Medicus' ROE % has ranged from 2.93 to 15.86. According to the industry distribution chart, ICARES Medicus ranks #380 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 47.7%.
Is ICARES Medicus' ROE % too high?
ICARES Medicus' current ROE % of 4.14% is 54% below median its 10-year median of 9.04. Over the past 10 years, this metric has ranged from a low of 2.93 to a high of 15.86. The Medical Devices & Instruments industry median ROE % is 2.40. ICARES Medicus' value of 4.14% is 72.5% above this industry median. Based on the distribution chart, ICARES Medicus ranks #380 out of 797 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ICARES Medicus has a GF Score™ of 84/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ICARES Medicus' ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, ICARES Medicus ranks #380 out of 797 companies for ROE %. This puts ICARES Medicus in the upper half of its industry. The industry median ROE % is 2.40. ICARES Medicus' value of 4.14% is 72.5% above this benchmark. Historically, ICARES Medicus' own ROE % has ranged from 2.93 to 15.86 over the past decade. While the company's 10-year median is 9.04 vs. the industry median of 2.40, ICARES Medicus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICARES Medicus's current ROE % of 4.14% is 72.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ICARES Medicus and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICARES Medicus's current ROE % is 4.14%, which is 54% below median its own 10-year median of 9.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICARES Medicus stock overvalued right now?
Based on GuruFocus' analysis, ICARES Medicus (ROCO:6612) is currently considered Possible Value Trap. The stock's GF Value™ is NT$189.06, compared to a current price of NT$71.30 — trading 62.3% below its estimated fair value. The current ROE % is 4.14%, which is 54% below median its 10-year median of 9.04 and 72.5% above the Medical Devices & Instruments industry median of 2.40. ICARES Medicus' overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For ICARES Medicus (ROCO:6612), the current ROE % is 4.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICARES Medicus (ROCO:6612) Overvalued in 2026?
Based on GuruFocus' analysis, ICARES Medicus stock appears to be undervalued.
The current stock price of NT$71.30 is trading 62.3% below its estimated GF Value™ of NT$189.06.
GuruFocus considers ICARES Medicus to be Possible Value Trap.
Key valuation signals for ROCO:6612:
ROE %: 4.14% (54% below median its 10-year median of 9.04)
GF Value™: NT$189.06 vs. price of NT$71.30 (62.3% below fair value)
Industry Position: 72.5% above the Medical Devices & Instruments median (#380 of 797)
No single metric tells the full story. See the ROCO:6612 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICARES Medicus Inc is engaged in providing high-grade nanomedical lubricious coatings and various surface treatments for implantable or interventional medical devices. In addition, it also designs, develops, manufactures, and sells intraocular lenses and nanomedical devices. The company's operating segments are Europe and America, which derive maximum revenue, China, and R.O.C. Geographically, it generates maximum revenue from the United States, followed by Taiwan, Spain, England, Japan, China, Germany, and other countries.
84GF Score
Get the complete analysis for ROCO:6612
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6612 has been successfully added to your 
